Cargando...
Do we always need to treat patients with spinal muscular atrophy? A personal view and experience
BACKGROUND: We report the clinical outcomes observed in our patients with SMA type 1 or 2 receiving nusinersen, and we comment on the ethical implications of this treatment, in line with our results and those reported by Audic et al. in their analysis published in the Orphanet Journal of Rare Diseas...
Gardado en:
| Publicado en: | Orphanet J Rare Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7879688/ https://ncbi.nlm.nih.gov/pubmed/33573692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-020-01593-4 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|